BR0302424A - Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral - Google Patents

Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral

Info

Publication number
BR0302424A
BR0302424A BR0302424-5A BR0302424A BR0302424A BR 0302424 A BR0302424 A BR 0302424A BR 0302424 A BR0302424 A BR 0302424A BR 0302424 A BR0302424 A BR 0302424A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
retroviral protease
preparing
oral administration
protease inhibitor
Prior art date
Application number
BR0302424-5A
Other languages
English (en)
Inventor
Ogari De Castro Dr Pacheco
Elisa Mannochio De Souza Russo
Valter Freire Torres Russo
Original Assignee
Cristalia Prod Quimicos Farm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm filed Critical Cristalia Prod Quimicos Farm
Priority to BR0302424-5A priority Critical patent/BR0302424A/pt
Priority to US10/565,220 priority patent/US20060217320A1/en
Priority to PCT/BR2004/000118 priority patent/WO2005007069A2/en
Priority to EP04737712A priority patent/EP1660522A4/en
Publication of BR0302424A publication Critical patent/BR0302424A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COM BIODISPONIBILIDADE AMPLIADA ADEQUADA A ADMINISTRAçãO ORAL DE INIBIDORES DA PROTEASE RETROVIRAL. PROCESSO DE PREPARAçãO DE COMPOSIçãO FARMACêUTICA CONCENTRADA CONTENDO INIBIDOR DA PROTEASE RETROVIRAL". A presente invenção descreve uma composição farmacêutica com biodisponibilidade ampliada, adequada a confecção de microcápsulas para a administração terapêutica de um inibidor de protease. é descrito também um processo de preparação de composição farmacêutica com biodisponibilidade ampliada, adequado ao preparo de composições farmacêuticas concentradas de inibidores da protease retroviral.
BR0302424-5A 2003-07-23 2003-07-23 Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral BR0302424A (pt)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR0302424-5A BR0302424A (pt) 2003-07-23 2003-07-23 Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral
US10/565,220 US20060217320A1 (en) 2003-07-23 2004-07-19 Soft gel formulations for saquinavir
PCT/BR2004/000118 WO2005007069A2 (en) 2003-07-23 2004-07-19 Soft gel formulations for saquinavir
EP04737712A EP1660522A4 (en) 2003-07-23 2004-07-19 PHARMACEUTICAL COMPOSITION WITH INCREASED BIOAVAILABILITY SUITABLE FOR THE ADMINISTRATION OF ORAL INHIBITORS OF RETROVIRAL PROTEASE. METHOD FOR PRODUCING A CONCENTRATED PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF RETROVIRAL PROTEASE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0302424-5A BR0302424A (pt) 2003-07-23 2003-07-23 Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral

Publications (1)

Publication Number Publication Date
BR0302424A true BR0302424A (pt) 2005-03-29

Family

ID=36204663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0302424-5A BR0302424A (pt) 2003-07-23 2003-07-23 Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral

Country Status (4)

Country Link
US (1) US20060217320A1 (pt)
EP (1) EP1660522A4 (pt)
BR (1) BR0302424A (pt)
WO (1) WO2005007069A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010095142A2 (en) * 2009-02-17 2010-08-26 Hetero Research Foundation Novel polymorphs of saquinavir

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439437A (en) * 1981-04-28 1984-03-27 Smith Kline & French Laboratories Limited 2-[2-Thiazolyl or 2-guanidino-4-thiazolyl methylthioethyl(or butyl)amino]-3-(hydroxy or carboxy)pyridines, compositions containing same and method of use
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
KR100587551B1 (ko) * 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
CA2326349A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations

Also Published As

Publication number Publication date
US20060217320A1 (en) 2006-09-28
WO2005007069A2 (en) 2005-01-27
EP1660522A4 (en) 2009-09-16
EP1660522A2 (en) 2006-05-31
WO2005007069A3 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
BR0206955A (pt) Ligantes de receptores de canabinóides
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
NO20043367L (no) Oralt farmasoytisk preparat
HUP0303128A2 (hu) O-dezmetil-venlafaxin új szukcinátsója, eljárás az előállításukra, alkalmazása és ezt tartalmazó gyógyszerkészítmény
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
CR7069A (es) Derivados de pirazol para el tratamiento de vih
UY27740A1 (es) Nuevos compuestos
BR0113234A (pt) Polimorfos de um análogo de epotilona
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
SE0302760D0 (sv) New compounds
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
BR0107564A (pt) Composição de gliburida
BR0314182A (pt) Formulações compreendendo um composto de indolinona
BR0209845A (pt) Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
UY27700A1 (es) Compuestos oxo - azabiclícos.
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
DOP2002000390A (es) Sal citrato de 5,8 14-hiezatetraciclo [10.3.1.0 2,11. 0.4.9] hexadeca-2(11),3,5,8,9, pentaeno y composiciones farmaceuticas de las mismas
SE0102440D0 (sv) New compound
AR040441A1 (es) Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2316 DE 26-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.